IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapiesMatthias Friedrich, Kévin Rue-Albrecht, Zoe Christoforidou et al.|Nature Medicine|2021Cited by 289
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseTom Thomas, Christopher D. Buckley, Matthias Friedrich et al.|Nature Immunology|2024Cited by 83
Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitorsRakesh Kumar Singh, Ruchi Tandon|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1